PEDIACARE CHILDREN'S ALLERGY OTC
Generic Name and Formulations:
Diphenhydramine HCl 12.5mg; per 5mL; liq; cherry-flavor, alcohol-free, contains sodium 14mg/5mL.
McNeil Consumer Healthcare
Indications for PEDIACARE CHILDREN'S ALLERGY:
Rhinorrhea, sneezing, allergy symptoms.
<4yrs: do not use. 4–5yrs: not recommended. 6–11yrs: 5mL every 4 hours; max 6 doses/24 hours.
Children <4yrs old. Concomitant other diphenhydramine products (including topicals). For use as a sedative hypnotic.
Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders.
See Contraindications. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, excitability.
Liq—4oz (w. dosing cup)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC